Check Cap Ltd (NASDAQ:CHEK) has been assigned a consensus broker rating score of 1.33 (Strong Buy) from the three brokers that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a buy rating and two have given a strong buy rating to the company. Check Cap’s rating score has improved by 11.3% from three months ago as a result of various analysts’ ratings changes.

Brokerages have set a 1 year consensus price target of $3.00 for the company and are forecasting that the company will post ($0.14) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Check Cap an industry rank of 80 out of 254 based on the ratings given to its competitors.

CHEK has been the subject of several recent analyst reports. HC Wainwright restated a “buy” rating and set a $2.00 target price on shares of Check Cap in a research report on Thursday. Zacks Investment Research lowered Check Cap from a “buy” rating to a “hold” rating in a research report on Wednesday.

CHEK traded down $0.00 on Tuesday, hitting $0.53. The company had a trading volume of 42,855 shares. The company has a market cap of $5.72 million and a PE ratio of -0.32. Check Cap has a 12-month low of $0.44 and a 12-month high of $2.57. The business’s fifty day simple moving average is $0.64 and its 200 day simple moving average is $1.36.

Check Cap (NASDAQ:CHEK) last released its quarterly earnings results on Wednesday, May 27th. The medical research company reported ($0.34) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.36) by $0.02. On average, sell-side analysts anticipate that Check Cap will post -1.03 EPS for the current year.

About Check Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient's back for capsule control, tracking, and data recording; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface.

See Also: What is the CAC 40 Index?

Get a free copy of the Zacks research report on Check Cap (CHEK)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with's FREE daily email newsletter.